Q2 2025 PAVmed Inc Earnings Call Transcript
Key Points
- PAVmed Inc (PAVM) reported a 40% increase in revenue from the first quarter, reaching $1.2 million, which matches their previous quarterly high.
- The company has partnered with Hoag, a large health system in Orange County, California, to launch a comprehensive EsoGuard esophageal precancer testing program.
- PAVmed Inc (PAVM) has secured its first positive commercial coverage policy with Highmark Blue Cross Blue Shield, covering Upstate New York.
- The company strengthened its balance sheet with an underwritten public offering, netting $16.1 million in proceeds, and now has $30 million in proforma cash.
- PAVmed Inc (PAVM) is well-positioned to capitalize on the large market opportunity for EsoGuard, with proactive steps being taken to accelerate commercialization once Medicare coverage is secured.
- The process of securing Medicare coverage for EsoGuard is complex and has been delayed, with the final coverage determination expected to take additional time.
- The company is currently operating with a quarterly burn rate of $10.3 million, which could impact financial stability if revenue growth does not accelerate.
- Revenue recognition is limited due to the early stages of the reimbursement process, with the majority of claims recognized only upon collection.
- The company faces challenges in expanding its Medicare patient base, as current efforts have not significantly targeted this demographic.
- PAVmed Inc (PAVM) is dependent on securing additional commercial coverage policies to drive revenue growth, which may take time to materialize.
Good morning, and welcome to the Lucid Diagnostics Second Quarter 2025 Business Update Conference Call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics Senior Director of Investor Relations.
Thank you, operator, and good morning, everyone, and thank you for participating in today's business update call.
Joining me today on the call are Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics, along with Dennis McGrath, Chief Financial Officer.
The press release announcing our business update and financial results is available on Lucid's website. Please take a moment to read the disclaimers about forward-looking statements in the press release.
The business update press release and the conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
